Are HPV‐negative lesions concerned for the introduction of primary HPV testing for cervical cancer screening in Japan?

Abstract

AbstractAimIn Japan, primary human papilloma virus (HPV) testing has not been introduced for cervical cancer screening due to concerns that HPV‐negative lesions may be missed and a lack of Japanese data. The purpose of this study was to evaluate the validity of primary HPV testing in Japan by analyzing cervical intraepithelial neoplasia 2 (CIN2) or more/high‐risk HPV− (CIN2+/hrHPV−) cases in cervical cancer screening.MethodsData from 35 525 cervical cancer screenings with HPV testing and cervical cytology from 2011 to 2019 in Saga City, Japan, were reviewed. The cases with low‐grade squamous intraepithelial lesion (LSIL+)/hrHPV− were analyzed in detail.ResultsThe results of the 35 525 examinees were as follows: 31 123 were negative for intraepithelial lesion or malignancy (NILM)/hrHPV–, 2612 were NILM/hrHPV+, 262 were atypical squamous cells of undetermined significance (ASC‐US)/hrHPV–, 213 were ASC‐US/hrHPV+, 291 were LSIL+/hrHPV−, and 1024 were LSIL+/hrHPV+. Of the 256 LSIL+/hrHPV− examinees for whom histology was available, CIN2+ were CIN2 9.4% (24/256), CIN3 3.9% (10/256), cervical adenocarcinoma 0.4% (1/256), uterine corpus cancer 1.2% (3/256), and uterine sarcoma 0.4% (1/256). Overall, the rate of LSIL+/hrHPV− was 0.82% (291/35.525), 0.1% (36/35525) of which were cervical lesions with CIN2+. Only one cervical adenocarcinoma was detected, but gastric‐type adenocarcinoma was not included.ConclusionHPV‐negative CIN2+ or cervical adenocarcinoma is not a concern for the introduction of primary HPV screening in Japan. Primary HPV testing in cervical cancer screening is considered a feasible method that can be used in Japan, although an algorithm suitable for Japan and a national‐level management system need to be established.